We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

86 hedge funds and large institutions have $393M invested in Vanda Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more call options, than puts

Call options by funds: $36M | Put options by funds: $17.1M

67% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 21

13% more capital invested

Capital invested by funds: $348M → $393M (+$45.7M)

13% less funds holding

Funds holding: 99 → 86 (-13)

39% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 33

Holders
86
Holders Change
-13
Holders Change %
-13.13%
% of All Funds
2.5%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
20
Increased
35
Reduced
21
Closed
33
Calls
$36M
Puts
$17.1M
Net Calls
+$18.9M
Net Calls Change
-$1.46M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.9M
2
O
OrbiMed
New York
+$9.94M
3
AGA
Altrinsic Global Advisors
Connecticut
+$4.02M
4
PAI
Palo Alto Investors
California
+$3.32M
5
BIM
Bogle Investment Management
Massachusetts
+$3.31M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$9.51M
2
Deutsche Bank
Deutsche Bank
Germany
-$6.12M
3
Wells Fargo
Wells Fargo
California
-$5.94M
4
PC
Pier Capital
Connecticut
-$5.33M
5
Jennison Associates
Jennison Associates
New York
-$4.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
JGC
51
J. Goldman & Co
New York
$732K -$211K -21,000 -26%
Deutsche Bank
52
Deutsche Bank
Germany
$668K -$6.12M -609,847 -92%
D.E. Shaw & Co
53
D.E. Shaw & Co
New York
$644K +$521K +51,864 New
WMSA
54
Weiss Multi-Strategy Advisers
New York
$621K +$100K +10,000 +25%
Charles Schwab
55
Charles Schwab
California
$587K – – –
TD Asset Management
56
TD Asset Management
Ontario, Canada
$586K +$474K +47,200 New
TA
57
Teachers Advisors
New York
$576K +$37.3K +3,710 +9%
Prudential Financial
58
Prudential Financial
New Jersey
$544K -$427K -42,500 -49%
AllianceBernstein
59
AllianceBernstein
Tennessee
$536K – – –
State Board of Administration of Florida Retirement System
60
State Board of Administration of Florida Retirement System
Florida
$520K – – –
CS
61
Credit Suisse
Switzerland
$504K +$111K +11,029 +37%
Ameriprise
62
Ameriprise
Minnesota
$474K -$507K -50,515 -57%
LTFS
63
Ladenburg Thalmann Financial Services
Florida
$372K -$15.1K -1,500 -5%
RhumbLine Advisers
64
RhumbLine Advisers
Massachusetts
$370K +$18.2K +1,810 +6%
MCM
65
Munder Capital Management
Michigan
$352K -$401K -39,891 -58%
VOYA Investment Management
66
VOYA Investment Management
Georgia
$320K – – –
MLICM
67
Metropolitan Life Insurance Company (MetLife)
New York
$314K – – –
CI
68
Cowen Inc
New York
$310K +$251K +25,000 New
ST
69
Spot Trading
Illinois
$290K +$235K +23,366 New
AIG
70
American International Group
New York
$273K +$30.2K +3,007 +16%
DekaBank Deutsche Girozentrale
71
DekaBank Deutsche Girozentrale
Germany
$240K +$5.02K +500 +3%
PPA
72
Parametric Portfolio Associates
Washington
$232K +$48.1K +4,789 +34%
MWNA
73
Marshall Wace North America
New York
$224K +$181K +18,036 New
SO
74
STRS Ohio
Ohio
$216K -$20.1K -2,000 -10%
ProShare Advisors
75
ProShare Advisors
Maryland
$211K -$156K -15,559 -48%
1 2
3
4 5

VNDA Hedge Fund Activity: Q4 2013 in Review

86 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2013, worth a combined $393M — up 13% from $348M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of VNDA and 20 opened new positions — a net loss of 13 holders — while 21 trimmed existing stakes and 35 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $11.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.51M sold.

  • 86 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2013, down from 99 in Q3 2013.
  • Funds reported $393M of Vanda Pharmaceuticals stock for Q4 2013, up 13% quarter-over-quarter.
  • 20 funds opened new Vanda Pharmaceuticals positions in Q4 2013 and 33 closed out, a net change of -13 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2013 was T. Rowe Price Associates, an estimated $11.9M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2013 was Perceptive Advisors, an estimated $9.51M sold.

Based on aggregated 13F filings for Q4 2013.